Financials

  • Market Capitalization 2.76 B
  • Employee 622
  • Founded 2002
  • CEO N/A
  • Website www.axogeninc.com
  • Headquarter Minnesota, United States
  • FIGI BBG000BN46R9
  • Industry Medical Devices
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-96.26
Price to sales ratio
6.69

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
1515
IRTC
iRhythm Holdings, Inc. - Common Stock
120.43 USD+3.52%-5.91%+3.54%-33.18%3.97 B USD
1694
TMDX
TransMedics Group, Inc. - Common Stock
90.06 USD-1.84%-4.59%+19.78%-22.75%3.12 B USD
1904
UFPT
UFP Technologies, Inc. - Common Stock
301.42 USD+0.49%-2.18%+18.04%+48.33%2.33 B USD
1909
BFLY
Butterfly Network, Inc. Class A Common Stock
8.43 USD-3.44%-9.65%+17.90%+410.91%2.24 B USD

Frequently asked questions about Axogen, Inc. Common Stock

What is the Axogen, Inc. Common Stock stock price today?

The current price of Axogen, Inc. Common Stock (AXGN) is 51.26. Over the past 24 hours, the stock has changed by -0.91%. Follow the AXGN chart for real-time price dynamics.

What is the stock ticker of Axogen, Inc. Common Stock?

Axogen, Inc. Common Stock trades under the ticker AXGN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Axogen, Inc. Common Stock stock going up?

AXGN has changed by +2.75% over the last week, +33.80% over the last month, and +181.03% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Axogen, Inc. Common Stock?

Axogen, Inc. Common Stock currently has a market capitalization of 2.76 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Axogen, Inc. Common Stock release financial reports?

Yes. You can track Axogen, Inc. Common Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were Axogen, Inc. Common Stock earnings last quarter?

Last quarter, Axogen, Inc. Common Stock reported earnings of -0.03 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Axogen, Inc. Common Stock revenue for the last quarter?

Axogen, Inc. Common Stock reported quarterly revenue of 69.73 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Axogen, Inc. Common Stock net income for the last quarter?

Axogen, Inc. Common Stock reported net income of -1.52 M for the last quarter. The previous quarter showed -19.58 M, which means net income changed by +92.26%.

How many employees does Axogen, Inc. Common Stock have?

As of the latest available data, Axogen, Inc. Common Stock has 622 employees. Workforce size can provide additional context about the company's scale and operations.

What is Axogen, Inc. Common Stock EBITDA?

Axogen, Inc. Common Stock EBITDA is 18.51 M, and its EBITDA margin is 26.54%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Axogen, Inc. Common Stock stock?

You can buy Axogen, Inc. Common Stock (AXGN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Axogen, Inc. Common Stock stock?

Investing in Axogen, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AXGN chart and related analysis on metatrader.com as part of your research.

Axogen, Inc. - Common Stock

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use.

News